Drug Discovery
By
Is NVIDIA’s 2025 Healthcare AI Report the Tipping Point for 80% of Providers and Pharma to Redefine Efficiency and Innovation?
Key Highlights Healthcare Sees Rapid ROI with Generative AIAccording to NVIDIA’s 2025 State of AI in Healthcare and…
Could Everest Medicines’ AI-Powered mRNA Platform Signal a Turning Point for Cancer and Autoimmune Therapies in Asia?
Key Highlights Reimagining Cancer Vaccines with AI-Optimized PersonalizationAt the 2025 Everest Medicines R&D Day, the company showcased EVM16,…
Shift Bioscience Unveils AI Framework to Improve Gene Target Discovery for Rejuvenation Therapies
Key Highlights Deeper DiveCambridge-based Shift Bioscience is rethinking how AI models are evaluated for rejuvenation research. Their study,…
Can Syntis Bio’s $38M Series A Transform Oral Biologics for Obesity and Rare Diseases?
Key Highlights Funding to Advance Novel Oral TherapiesBoston-based Syntis Bio announced the close of its $38 million financing…
Can GSK’s Gepotidacin Priority FDA Review and Strategic Acquisitions Accelerate Its Antibiotic and Specialty Medicine Leadership in 2025?
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
